ABC ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 1 |
| 325 | Hereditary autoinflammatory syndrome | 1 |
265. Lipodystrophy
Clinical trials : 116 / Drugs : 170 - (DrugBank : 61) / Drug target genes : 26 - Drug target pathways : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00865007 (ClinicalTrials.gov) | December 2008 | 18/3/2009 | Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy | A Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/Ritonavir | HIV Infection;Lipodystrophy;HIV Infections | Drug: Monotherapy (Lopinavir/ritonavir);Drug: Monotherapy (Lopinavir/ritonavir) + ABC/3TC | Fundacion SEIMC-GESIDA | Abbott | Completed | 18 Years | N/A | Both | 88 | Phase 4 | Spain |
325. Hereditary autoinflammatory syndrome
Clinical trials : 7 / Drugs : 16 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04731103 (ClinicalTrials.gov) | February 2022 | 14/7/2020 | Inhibition of Reverse Transcription in Type I Interferon Mediated Neuropathology | Inhibition of Reverse Transcription in Type I Interferon Mediated Neuropathology | Aicardi-Goutières Syndrome | Drug: Abacavir (ABC);Drug: Lamivudine (3TC);Drug: Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT) | University of Edinburgh | NHS Lothian;Medical Research Council | Not yet recruiting | 3 Months | 15 Years | All | 24 | Phase 2 | United Kingdom |